Vaxart (OTCMKTS:VXRT) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Vaxart (OTCMKTS:VXRT) announced its earnings results on Thursday. The biotechnology company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.06, Zacks reports. Vaxart had a net margin of 14.51% and a return on equity of 61.43%.

Vaxart Price Performance

Shares of OTCMKTS:VXRT traded down $0.02 on Thursday, hitting $0.57. 181,566 shares of the company’s stock were exchanged, compared to its average volume of 557,097. The stock has a market capitalization of $138.42 million, a price-to-earnings ratio of 3.80 and a beta of 1.10. Vaxart has a 12 month low of $0.30 and a 12 month high of $0.84. The business’s 50 day simple moving average is $0.56 and its two-hundred day simple moving average is $0.63.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. increased its position in Vaxart by 16.9% during the 2nd quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock valued at $107,000 after purchasing an additional 34,075 shares during the period. Invesco Ltd. raised its holdings in shares of Vaxart by 93.1% in the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock valued at $60,000 after purchasing an additional 70,568 shares in the last quarter. Creative Planning purchased a new stake in shares of Vaxart in the 2nd quarter worth approximately $33,000. Goldman Sachs Group Inc. purchased a new stake in shares of Vaxart in the 1st quarter worth approximately $31,000. Finally, Jones Financial Companies Lllp boosted its stake in shares of Vaxart by 276,364.7% during the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock valued at $196,000 after purchasing an additional 478,111 shares in the last quarter. Hedge funds and other institutional investors own 18.05% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded shares of Vaxart to a “hold” rating in a report on Thursday, July 9th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, Vaxart currently has an average rating of “Hold”.

Vaxart Company Profile

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.